Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 02 2021
Historique:
received: 30 01 2020
accepted: 01 07 2020
pubmed: 4 7 2020
medline: 1 10 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Leishmania skin test (LST) evaluates the delayed type hypersensitivity to Leishmania antigens (LA) and has been used for diagnosis of cutaneous leishmaniasis (CL). In CL patients LST is usually positive but a small percentage have negative LST. The aim of this study was to determine the clinical and immunologic features and response to antimony therapy in LST-negative CL patients. We compare the clinical presentation, response to therapy, and immune response of CL patients with negative vs positive LST. The clinical presentation was similar in both groups but LST-negative patients had a lower cure rate. In the lesions, LST-negative patients displayed less inflammation and necrosis, and higher frequency of CD8+ T cells. Mononuclear cells from LST-negative patients had a poor T helper 1 cell (Th1) response but levels of interleukin-1β (IL-1β), IL-6, IL-17, granzyme B, and metalloproteinase-9 (MMP-9) were similar to the LST-positive group upon stimulation with LA. Leishmania internalization and killing by macrophages were similar in both groups. Cure of disease was associated with restoration of Th1 response. In LST-negative patients, impaired Th1 response is associated with therapeutic failure. Increased frequency of CD8+ T cells and high production of inflammatory cytokines, granzyme B, and MMP-9 contributes to immunopathology.

Sections du résumé

BACKGROUND
Leishmania skin test (LST) evaluates the delayed type hypersensitivity to Leishmania antigens (LA) and has been used for diagnosis of cutaneous leishmaniasis (CL). In CL patients LST is usually positive but a small percentage have negative LST. The aim of this study was to determine the clinical and immunologic features and response to antimony therapy in LST-negative CL patients.
METHODS
We compare the clinical presentation, response to therapy, and immune response of CL patients with negative vs positive LST.
RESULTS
The clinical presentation was similar in both groups but LST-negative patients had a lower cure rate. In the lesions, LST-negative patients displayed less inflammation and necrosis, and higher frequency of CD8+ T cells. Mononuclear cells from LST-negative patients had a poor T helper 1 cell (Th1) response but levels of interleukin-1β (IL-1β), IL-6, IL-17, granzyme B, and metalloproteinase-9 (MMP-9) were similar to the LST-positive group upon stimulation with LA. Leishmania internalization and killing by macrophages were similar in both groups. Cure of disease was associated with restoration of Th1 response.
CONCLUSIONS
In LST-negative patients, impaired Th1 response is associated with therapeutic failure. Increased frequency of CD8+ T cells and high production of inflammatory cytokines, granzyme B, and MMP-9 contributes to immunopathology.

Identifiants

pubmed: 32620011
pii: 5867185
doi: 10.1093/infdis/jiaa374
pmc: PMC7881333
doi:

Substances chimiques

Cytokines 0
Antimony 9IT35J3UV3
Granzymes EC 3.4.21.-
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-535

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI136032
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Infect Dis. 2009 Jul 1;200(1):75-8
pubmed: 19476435
J Infect Dis. 1993 Mar;167 Suppl 1:S13-7
pubmed: 8433014
Int J Dermatol. 1995 Jul;34(7):474-9
pubmed: 7591410
Clin Infect Dis. 2008 Jan 15;46(2):223-31
pubmed: 18171254
PLoS Pathog. 2013;9(7):e1003504
pubmed: 23874205
J Clin Microbiol. 2011 Nov;49(11):3892-904
pubmed: 22042830
Am J Trop Med Hyg. 1995 Sep;53(3):256-9
pubmed: 7573708
Infect Immun. 2002 Dec;70(12):6734-40
pubmed: 12438348
PLoS Negl Trop Dis. 2012;6(12):e1947
pubmed: 23285304
J Trop Med Hyg. 1986 Dec;89(6):319-23
pubmed: 3806749
J Infect Dis. 2015 Jul 1;212(1):157-65
pubmed: 25596303
PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3282
pubmed: 25393535
Am J Trop Med Hyg. 2009 Apr;80(4):574-9
pubmed: 19346378
J Infect Dis. 2005 Dec 1;192(11):1981-7
pubmed: 16267771
J Infect Dis. 2002 Dec 15;186(12):1829-34
pubmed: 12447770
Br J Dermatol. 2009 Feb;160(2):311-8
pubmed: 19187345
J Infect Dis. 2016 Aug 15;214(4):570-6
pubmed: 27190181
J Infect Dis. 2015 Jan 15;211(2):274-82
pubmed: 25139016
PLoS Negl Trop Dis. 2016 Feb 01;10(2):e0004422
pubmed: 26829554
Acta Trop. 1994 Apr;56(4):315-25
pubmed: 8023755
Acta Trop. 2011 Aug;119(2-3):160-4
pubmed: 21663729
J Invest Dermatol. 2013 Jun;133(6):1533-40
pubmed: 23321919
Epidemiol Infect. 1995 Apr;114(2):297-318
pubmed: 7705493
Am J Trop Med Hyg. 2017 Mar;96(3):645-652
pubmed: 28115669
Clin Infect Dis. 2002 Jun 15;34(12):E69-73
pubmed: 12032913
Parasite Immunol. 2009 Aug;31(8):423-31
pubmed: 19646206
PLoS Pathog. 2017 Feb 13;13(2):e1006196
pubmed: 28192528
J Immunol. 2008 May 1;180(9):6139-48
pubmed: 18424735
J Immunol. 1997 Nov 1;159(9):4467-73
pubmed: 9379046
J Invest Dermatol. 2018 May;138(5):1107-1115
pubmed: 29246797
Immunol Rev. 2000 Feb;173:17-26
pubmed: 10719664
Clin Infect Dis. 2002 Jun 1;34(11):E54-8
pubmed: 12015707
Front Immunol. 2012 Oct 04;3:301
pubmed: 23060880
Am J Trop Med Hyg. 1986 Jan;35(1):79-85
pubmed: 3946739
Mem Inst Oswaldo Cruz. 1991 Jan-Mar;86(1):51-6
pubmed: 1842401
Trans R Soc Trop Med Hyg. 1994 Jul-Aug;88(4):386-8
pubmed: 7570812
Nature. 2002 Dec 5;420(6915):502-7
pubmed: 12466842
J Infect Dis. 1992 Mar;165(3):535-40
pubmed: 1347057
Infect Immun. 2015 Mar;83(3):898-906
pubmed: 25534940
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e912
pubmed: 21200420
BMC Infect Dis. 2013 Nov 09;13:529
pubmed: 24206576
J Infect Dis. 1992 Nov;166(5):1124-32
pubmed: 1402024
PLoS Negl Trop Dis. 2012;6(5):e1533
pubmed: 22629474
Parasite Immunol. 2009 Aug;31(8):432-9
pubmed: 19646207
J Invest Dermatol. 2020 Jan;140(1):246-249.e2
pubmed: 31252034
Sci Transl Med. 2019 Nov 20;11(519):
pubmed: 31748229
J Infect Dis. 2007 Jun 15;195(12):1846-51
pubmed: 17492601

Auteurs

Augusto M Carvalho (AM)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.

Luiz H Guimarães (LH)

Universidade Federal do Sul da Bahia, Teixeira de Freitas, Brazil.

Rúbia Costa (R)

Instituto Nacional de Ciência e Tecnologia me Doenças Tropicais, Salvador, Bahia, Brazil.

Maíra G Saldanha (MG)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.

Iana Prates (I)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.

Lucas P Carvalho (LP)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Instituto Nacional de Ciência e Tecnologia me Doenças Tropicais, Salvador, Bahia, Brazil.

Sérgio Arruda (S)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.
Instituto Nacional de Ciência e Tecnologia me Doenças Tropicais, Salvador, Bahia, Brazil.

Edgar M Carvalho (EM)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Instituto Nacional de Ciência e Tecnologia me Doenças Tropicais, Salvador, Bahia, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH